Neurology® Podcast Exploring GLP-1 Receptor Agonists for Neurodegeneration
Feb 27, 2025
Dr. Lorraine Kalia, an associate professor of neurology at the University of Toronto and senior scientist at the Krembil Brain Institute, dives into the intriguing world of GLP-1 receptor agonists as potential treatments for neurodegenerative diseases. She shares insights on the mixed results from recent clinical trials, notably with exenatide, and discusses the promising preclinical benefits such as reduced inflammation. Kalia emphasizes the challenges of translating lab findings to human applications, while pointing to the potential for these therapies in conditions like Parkinson's and Alzheimer's.
AI Snips
Chapters
Transcript
Episode notes
GLP-1 Agonists for Neurodegenerative Diseases
- GLP-1 agonists are being explored for neuroprotection in diseases like Parkinson's and Alzheimer's.
- A recent phase 3 trial on exenatide for Parkinson's disease modification did not show significant positive results.
Preclinical Evidence for GLP-1 Agonists
- Preclinical data suggested GLP-1 agonists could have neuroprotective effects through various mechanisms.
- These include reducing protein aggregation, inflammation, and potentially promoting neurogenesis.
GLP-1 Agonists in Alzheimer's Disease
- Similar to Parkinson's disease, preclinical studies in Alzheimer's show potential benefits of GLP-1 agonists.
- A phase 3 trial (EVOKE) on oral semaglutide for Alzheimer's is ongoing, with results expected in late 2025.